Direct answer. As of 30 October 2026, Caliway says its investigational CBL-514 is not commercially available in any market and that it has not authorized third parties to sell, supply or distribute it. A website using the name does not establish a connection to the developer.
What did the developer state on 30 October 2026?
In its 30 October clarification, Caliway Biopharmaceuticals identifies CBL-514 as an investigational drug candidate in clinical development. It says no country or jurisdiction has granted marketing approval and that the product is not commercially available. The company also says it has not authorized a third party to supply, distribute, market or sell CBL-514, or to present itself as an affiliate or agent. The statement applies to the developer’s program as of its publication date; Caliway directs readers to its own announcements for authoritative updates.
A buyer searching “CBL-514 peptide buy” may encounter a product photo, a nominal vial amount or a quotation form. None of those establishes that the seller can provide the developer’s clinical formulation. The published Phase II paper describes a studied small-molecule injection, whereas online listings may define their materials differently or not at all. This website is independent of Caliway. Its research pages discuss public evidence; they do not confer a supply relationship with the company.
What the statement answers
- Commercial availability of Caliway’s investigational CBL-514: no, according to Caliway on 30 October 2026.
- Third-party authorization: none claimed by the developer.
- A matching product name or vial label cannot establish identity or authorization.
How should a reader check a sales or supply claim?
Begin at the developer’s official site and read the dated statement itself. Then ask whether the seller can show a verifiable legal relationship, a defined substance or formulation, a batch-linked certificate and a traceable chain of custody. A certificate with no issuing entity or no link to the offered lot answers little. Even a genuine laboratory test of an independently sourced material cannot prove that it is Caliway’s investigational product unless the developer confirms the relationship.
Keep three questions separate in your notes: who controls the clinical program, what substance the third party actually offers, and whether the particular transaction is lawful in its destination. The supplier-claim checklist covers the second question at a practical level. If a listing suggests clinical use, repeats trial outcomes as product promises or calls itself “official” without evidence, record the exact claim and check it against the original notice. Research-use wording on a label does not undo a misleading identity or affiliation claim.
A useful verification record
- Save the dated developer statement and the seller’s exact wording.
- Require batch-specific identity and assay evidence for any independently described material.
- Do not treat a purchase listing as a clinical-trial access route.
What is the responsible next step for different readers?
A person looking for treatment should use qualified clinical care or an official study record, such as ClinicalTrials.gov, to find a study contact and eligibility criteria. A procurement team should document its own nonclinical project and pause any claim that the third-party material is the developer’s CBL-514 without direct proof. An investor or journalist should date the company statement and distinguish it from a vendor advertisement. The same keyword reaches all three audiences, but each needs a different source and decision.
This article will be reviewed when Caliway publishes a new statement or a regulator records a marketing decision. Until then, search results that advertise a “release date,” retail price or authorized CBL-514 supply have no support from the company’s 30 October announcement. The site’s trial-status guide explains why enrollment, study completion and publication are separate milestones. None of them by itself authorizes commercial distribution.
Where to go next
- Clinical participation: official registry and study contacts.
- Research procurement: independently verify identity, batch evidence and permitted scope.
- Current product status: the developer’s dated announcement.
Reviewed 31 October 2026. This editorial review summarizes named public sources and does not offer treatment or identify any third-party vial as the developer’s clinical formulation.
Frequently asked questions
Is Caliway’s CBL-514 commercially available?
Caliway stated on 30 October 2026 that its investigational CBL-514 had no marketing approval and was not commercially available in any market.
Has Caliway authorized online sellers of CBL-514?
The same statement says it has not authorized any third party to supply, distribute, market or sell CBL-514 or imply an affiliation.
Does “for research use only” prove a vial is the trial formulation?
No. That wording describes intended use on a label. It does not verify the substance, formulation, source or relationship to the developer.
Where can a reader check a clinical trial?
Use the official ClinicalTrials.gov record and its listed study contacts. A third-party product page is not a route into a clinical trial.